Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07193485

Efficacy of Buteyko Breathing in Seniors With Chronic Eustachian Tube Dysfunction

Eustachian tube dysfunction is distressing probelm. drugs usually are not effective. compelemtary tehrapies like Buteyko breathing may be effective

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Eustachian Tube Dysfunction

Age range

65 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cairo University

Dokki, Giza Governorate, 11432, Egypt

Location status: Recruiting

Location contact

ali AM Ismail, lecturer

CONTACT

[email protected]

+201005154209

About this study

forty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group I or group II. the group enroled 20 seniors. both groups wil take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks. group I will aslo receive 30-min Buteyko breathing two times daily for 14 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Eustachian Tube Dysfunction (chronic obstructive form)
  • unilateral ear affetion
  • senior patients
  • chronci affection more than 3 months

Exclusion criteria

  • obesity
  • cardiac probelms repsiratory problems

Treatment and study plan

Buteyko breathing

Other

twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group I and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks. Also, group I will aslo receive 30-min Buteyko breathing two times daily for 14 weeks.

Usual Care

Other

twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group II and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks.

Primary outcomes

  1. Eustachian Tube Dysfunction Questionnaire

    Time frame: it will be measured after 2 weeks

    it will be used to asses symptoms of Eustachian Tube Dysfunction

Secondary outcomes

  1. systolic blood pressure

    Time frame: it will be measured after 2 weeks

    it will be measured manually by manual sphygmomanometer

  2. diastolic blood pressure

    Time frame: it will be measured after 2 weeks

    it will be measured manually by manual sphygmomanometer

  3. respiratory rate

    Time frame: it will be measured after 2 weeks

    it will assess breath number per minute

  4. pulse rate

    Time frame: it will be measured after 2 weeks

    it will assess pulse number per minute from radial artery

  5. patient health questionnaire

    Time frame: it will be measured after 2 weeks

    it will assess depression in patients

  6. state trait anxiety inventory

    Time frame: it will be measured after 2 weeks

    it will assess trait anxiety in patients

  7. perceived stress scale

    Time frame: it will be measured after 2 weeks

    it will assess stress in patients

  8. short form 36 questionnaire

    Time frame: it will be measured after 2 weeks

    it will assess quality of life in patients

  9. profile of mood satus

    Time frame: it will be measured after 2 weeks

    it will assess mood in patients

  10. percenatge of tympanometry (type C)

    Time frame: it will be measured after 2 weeks

    it will assess percenatge of type c tympanometry

Study contacts

Contact information is provided by the study sponsor or research team.

Ali MA Ismail, lecturer

CONTACT

[email protected]

01005154209

Ali mohamed, lecturer

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Sep 25, 2025
Registry last updated
Sep 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.